Clinical Trials
208 trialsStudy to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Pfizer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
National Cancer Institute (NCI)
PREPARE
Institut Bergonié
RAF/MEK
Royal Marsden NHS Foundation Trust
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Seagen Inc.
INOVOLINE
Hospices Civils de Lyon
Study of ESG401 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
AMPLIFY-201
Elicio Therapeutics
EARN
Washington University School of Medicine
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Alaunos Therapeutics
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
PRIORITY
Institut Bergonié
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
EXODIAG
Centre Georges Francois Leclerc
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Continued Access to RXDX-105
Memorial Sloan Kettering Cancer Center
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1
Tomsk National Research Medical Center of the Russian Academy of Sciences
PREFER
Labcorp Corporation of America Holdings, Inc
ACTolog
Immatics US, Inc.
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
REMOVE
Lindis Bloodcare GmbH
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
ROOT
Taproot Health
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Study of Continuous OSI-906 Dosing
Astellas Pharma Inc
Study of Intermittent OSI-906 Dosing
Astellas Pharma Inc
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group